FAM71D Inhibitors
Inhibition of FAM71D involves a multifaceted approach targeting various signaling pathways and cellular processes that may regulate its activity. Kinase inhibitors play a crucial role in this context, as they can disrupt the phosphorylation status of proteins, potentially leading to decreased FAM71D activity if it is regulated by protein kinases. Additionally, the inhibition of the PI3K/AKT pathway, a key regulator of cell survival and growth, would consequentially lower FAM71D's functional activity if it were intertwined with this pathway. Similarly, the mTOR signaling pathway, which orchestrates protein synthesis and cell growth, when inhibited, might reduce the activity of FAM71D by limiting protein production. Furthermore, modulation of the cytoskeleton through ROCK kinase inhibition could affect FAM71D's activity if it is associated with actin dynamics, as the cytoskeleton influences protein interactions and cellular functions.
Moreover, targeting MAPK signaling pathways offers another dimension of control over FAM71D, as inhibition of the upstream kinases MEK and p38 MAPK, or JNK, could reduce FAM71D activity by dampening downstream signaling events. Alteration of gene expression patterns through histone deacetylase inhibition could also indirectly lower FAM71D activity, assuming FAM71D is regulated by such epigenetic modifications. Disruption of intracellular protein trafficking by compounds like Brefeldin A could impede FAM71D's activity by interfering with its proper localization within the cell. Additionally, specific MEK inhibitors that prevent ERK activation offer another layer of control over FAM71D by targeting the MAPK/ERK pathway, which may play a role in its regulation. By employing inhibitors that target PI3K, the subsequent decrease in AKT signaling could also inhibit FAM71D if it is regulated via this pathway. Lastly, the use of compounds like Cyclosporin A that inhibit calcineurin impacts T-cell activation and might also decrease FAM71D activity by affecting calcium signaling or immune response pathways that FAM71D may be a part of.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
This kinase inhibitor broadly targets protein kinases, leading to the inhibition of multiple signaling pathways. FAM71D, being a protein, could be regulated by such kinases; hence, inhibition of these kinases can result in decreased phosphorylation and subsequent activity of FAM71D. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A specific inhibitor of PI3K, which is part of the PI3K/AKT signaling pathway. FAM71D that might be involved in this pathway would have its activity reduced as a result of PI3K inhibition, which would alter downstream signaling involved in cell survival and growth. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that disrupts mTORC1 signaling, leading to altered protein synthesis and cell growth. FAM71D, potentially regulated by mTOR pathways, would have its functional activity inhibited through reduced protein synthesis. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
A selective inhibitor of ROCK kinases, which modulates actin cytoskeleton dynamics. FAM71D, if associated with cytoskeletal regulation, would have its activity inhibited as changes in actin dynamics can affect protein interactions and functions. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
An inhibitor of MEK, which acts upstream of ERK in the MAPK signaling pathway. If FAM71D is involved in this pathway, its activity would be inhibited through the suppression of downstream ERK signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
This compound inhibits p38 MAP kinase, affecting cellular responses to stress and inflammation. Inhibition of p38 may decrease FAM71D activity if it is involved in stress response signaling pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor that could suppress the JNK signaling pathway. If FAM71D operates within this pathway, its activity would be inhibited due to reduced JNK-mediated signaling events. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
A histone deacetylase inhibitor that alters chromatin structure and gene expression. FAM71D, if regulated by acetylation status, would exhibit decreased activity due to changes in the transcriptional landscape. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
This compound disrupts protein trafficking by inhibiting ADP-ribosylation factor. FAM71D activity could be inhibited if it relies on proper localization and trafficking within the cell. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
An MEK inhibitor that also prevents activation of ERK, another component of the MAPK pathway. FAM71D activity may be inhibited through the suppression of MEK/ERK signaling. | ||||||